Login / Signup

Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.

Anne K EllisD C TsitouraD QuintW PowleyL A Lee
Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017)
Weekly i.n. GSK2245035 20 ng was well tolerated and reduced allergic reactivity to nasal challenge for 3 weeks post-treatment.
Keyphrases
  • allergic rhinitis
  • signaling pathway
  • pi k akt
  • toll like receptor
  • immune response
  • cell proliferation
  • replacement therapy
  • gestational age
  • nuclear factor
  • chronic rhinosinusitis